Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $499M | $563M | $643M | $714M | $739M | $931M | $1.11B | $1.14B | $1.16B | $1.22B |
| Revenue growth | — | 12.8% | 14.2% | 11.0% | 3.5% | 26.0% | 18.7% | 2.8% | 2.0% | 5.2% |
| Gross profit | $337M | $375M | $432M | $473M | $483M | $633M | $756M | $770M | $770M | $790M |
| Gross margin | 67.5% | 66.5% | 67.2% | 66.3% | 65.4% | 68.0% | 68.4% | 67.7% | 66.4% | 64.8% |
| Operating income | $151M | $121M | $136M | $147M | $157M | $237M | $297M | $299M | $207M | $102M |
| Operating margin | 30.2% | 21.4% | 21.2% | 20.5% | 21.3% | 25.5% | 26.8% | 26.3% | 17.8% | 8.4% |
| Net income | $104M | $76.1M | $126M | $96.1M | $229M | $140M | $272M | $285M | $168M | $73.4M |
| Net margin | 20.9% | 13.5% | 19.6% | 13.5% | 31.0% | 15.1% | 24.6% | 25.1% | 14.5% | 6.0% |
| EPS (diluted) | $2.80 | $2.03 | $3.31 | $2.47 | $5.82 | $0.87 | $1.66 | $1.76 | $1.05 | $0.46 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $144M | $144M | $170M | $182M | $205M | $352M | $325M | $254M | $299M | $288M |
| Capital expenditures | $16.9M | $15.2M | $20.9M | $25.4M | $51.7M | $44.3M | $44.9M | $38.2M | $62.9M | $31.0M |
| Free cash flow | $127M | $129M | $149M | $156M | $153M | $308M | $280M | $216M | $236M | $257M |
| Share buybacks | — | — | $0.00 | $15.4M | $50.1M | $43.2M | $161M | $19.6M | $80.0M | $276M |
| Dividends paid | $47.6M | $47.3M | $48.0M | $48.4M | $48.9M | $49.6M | $50.2M | $50.3M | $50.4M | $50.4M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $64.2M | $91.6M | $122M | $101M | $147M | $199M | $173M | $181M | $152M | $162M |
| Total assets | $1.13B | $1.56B | $1.59B | $1.88B | $2.03B | $2.26B | $2.29B | $2.64B | $2.70B | $2.56B |
| Shareholders' equity | $879M | $950M | $1.08B | $1.17B | $1.38B | $1.57B | $1.70B | $1.97B | $2.07B | $1.92B |
| Retained earnings | $771M | $799M | $877M | $932M | $1.06B | $1.09B | $1.12B | $1.31B | $1.33B | $1.07B |
| Shares (wtd avg diluted) | 37.3M | 37.5M | 38.1M | 38.9M | 39.4M | 162M | 164M | 162M | 161M | 160M |
Every figure is extracted from BIO-TECHNE Corp’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.